ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,469.30
      0.39%
      US Tech 100
      19,230.40
      0.29%
      Dow Jones
      39,112.16
      -0.76%
      Brent Oil
      84.985
      0.95%
      Bitcoin
      61,270.97
      -0.87%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Keros Therapeutics Inc (KROS)

      7. Keros Therapeutics Inc (KROS) News

      KROS

      Keros Therapeutics (KROS)

      Keros Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:KROS
      DateTimeSourceHeadlineSymbolCompany
      06/17/20245:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      06/17/20245:15PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KROSKeros Therapeutics Inc
      06/17/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      06/17/20244:01PMGlobeNewswire Inc.Keros Therapeutics Announces Leadership UpdatesNASDAQ:KROSKeros Therapeutics Inc
      06/17/20246:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      06/17/20246:00AMGlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
      06/04/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      06/04/20248:00AMGlobeNewswire Inc.Keros Therapeutics to Host a Corporate Update Conference Call and WebcastNASDAQ:KROSKeros Therapeutics Inc
      06/03/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
      06/03/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
      06/03/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
      06/03/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      06/03/20248:00AMGlobeNewswire Inc.Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
      05/30/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      05/28/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      05/28/20244:01PMGlobeNewswire Inc.Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsNASDAQ:KROSKeros Therapeutics Inc
      05/14/202410:00AMGlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
      05/08/20248:03AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
      05/08/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      05/08/20248:00AMGlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
      03/14/20248:00AMGlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
      03/06/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      03/05/20248:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      03/05/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      03/05/20248:00AMGlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
      02/28/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
      02/28/20244:01PMGlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
      02/23/20245:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
      02/15/20248:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
      02/15/20248:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:KROS